The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...
William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...
Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). Top-line data of the phase ...
On Monday, AT&T Inc T reported better-than-expected fourth-quarter results. The company posted operating revenues of $32.30 ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...
With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...
Positive data for Veru Inc.’s enobosarm lend more weight to the potential progress of the company’s body-mass preservation program in patients taking Wegovy (semaglutide). The side effect of lean mass ...
Oppenheimer reiterated an Outperform rating on Veru Inc. (NASDAQ:VERU), which has seen remarkable momentum with a 200% return over the past year and a 96% gain year-to-date. Anticipation is building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback